The Effects of Escitalopram on Cytokines (BAFH)
This study is currently recruiting participants.
Verified May 2012 by Beitou Armed Forces Hospital, Taipei, Taiwan
Sponsor:
Beitou Armed Forces Hospital, Taipei, Taiwan
Information provided by (Responsible Party):
Beitou Armed Forces Hospital, Taipei, Taiwan
ClinicalTrials.gov Identifier:
NCT01587326
First received: April 26, 2012
Last updated: May 13, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The association of cytokines with escitalopram has not been investigated in patients with major depressive disorder (MDD). Hence, the investigators will examine this association.
| Condition | Intervention |
|---|---|
|
Depression |
Drug: Escitalopram |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Effects of Escitalopram on Cytokines in Depressive Patients |
Resource links provided by NLM:
Further study details as provided by Beitou Armed Forces Hospital, Taipei, Taiwan:
Primary Outcome Measures:
- The changes in cytokines [ Time Frame: Week 0, Week 4 ] [ Designated as safety issue: Yes ]Hamilton Depression Rating Scale, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1β, TNF-α
Secondary Outcome Measures:
- The changes in Hamilton Depression Rating Scale [ Time Frame: week 0, week 4 ] [ Designated as safety issue: Yes ]Hamilton Depression Rating Scale, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1β, TNF-α
| Estimated Enrollment: | 25 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Escitalopram
Escitalopram 10 mg/d to 20 mg/d
|
Drug: Escitalopram
escitalopram 10 mg/d to 20 mg/d
Other Name: Lexapro
|
Detailed Description:
In addition to serotonin, inflammatory process has been suggested in the development of major depressive disorder (MDD) and in its associated treatment. Escitalopram is an antidepressant that has been widely used in patients with MDD because of the promising results. The association of cytokines with escitalopram has not been investigated in patients with MDD. Hence, the investigators will examine this association.
Eligibility| Ages Eligible for Study: | 20 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- DSM-IV-defined Major depressive disorder, single episode
- Age 20-65
- Drug-naive
- Hamilton Depression Rating Scale exceeding 14 scores
Exclusion Criteria:
- Major medical disorders
- Substance use
- Pregnant
- Allergy to escitalopram
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01587326
Contacts
| Contact: Pei-Shen Ho, M.D. | +886-2-28959808 | luke_and_tina@yahoo.com.tw |
Locations
| Taiwan | |
| Beitou Armed Forces Hospital | Recruiting |
| Taipei, Taiwan | |
| Contact: Chih-Sung Liang, M.D. +886-2-8959808 lcsyfw@gmail.com | |
Sponsors and Collaborators
Beitou Armed Forces Hospital, Taipei, Taiwan
Investigators
| Study Chair: | Peishen Ho, M.D. | Beitou Armed Forces Hospital |
More Information
No publications provided
| Responsible Party: | Beitou Armed Forces Hospital, Taipei, Taiwan |
| ClinicalTrials.gov Identifier: | NCT01587326 History of Changes |
| Other Study ID Numbers: | BAFH-101-05, BAFH |
| Study First Received: | April 26, 2012 |
| Last Updated: | May 13, 2012 |
| Health Authority: | Taiwan : Food and Drug Administration |
Keywords provided by Beitou Armed Forces Hospital, Taipei, Taiwan:
|
cytokine, depression, escitalopram |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Dexetimide Citalopram Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Parasympatholytics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Serotonin Agents |
ClinicalTrials.gov processed this record on May 23, 2013